Ahorra tiempo para lo que te encanta. Inscríbete en el pago automático hoy mismo.
Políticas clínicas y de pago
Clinical Policies
Clinical policies are one set of guidelines used to assist in administering health plan benefits, either by prior authorization or payment rules. They include but are not limited to policies relating to evolving medical technologies and procedures, as well as pharmacy policies. Clinical policies help identify whether services are medically necessary based on information found in generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by the policy; and other available clinical information.
All policies found in the Ambetter of Tennessee Clinical Policy Manual apply to Ambetter of Tennessee members. Policies in the Ambetter of Tennessee Clinical Policy Manual may have either a Ambetter of Tennessee or a “Centene” heading. Ambetter of Tennessee utilizes InterQual® criteria for those medical technologies, procedures or pharmaceutical treatments for which a Ambetter of Tennessee clinical policy does not exist. InterQual is a nationally recognized evidence-based decision support tool. You may access the InterQual® SmartSheet(s)™ for Adult and Pediatric procedures, durable medical equipment and imaging procedures by logging into the secure provider portal or by calling Ambetter of Tennessee. In addition, Ambetter of Tennessee may from time to time delegate utilization management of specific services; in such circumstances, the delegated vendor’s guidelines may also be used to support medical necessity and other coverage determinations. Other non-clinical policies (e.g., payment policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Clinical Policy Manuals or InterQual®criteria is payable by Ambetter of Tennessee.
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
For a list of all active clinical policies, see below. For any upcoming policy changes, view the Clinical Policy Updates list.
Payment Policies
Health care claims payment policies are guidelines used to assist in administering payment rules based on generally accepted principles of correct coding. They are used to help identify whether health care services are correctly coded for reimbursement. Each payment rule is sourced by a generally accepted coding principle. They include, but are not limited to claims processing guidelines referenced by the Centers for Medicare and Medicaid Services (CMS), Publication 100-04, Claims Processing Manual for physicians/non-physician practitioners, the CMS National Correct Coding Initiative policy manual (procedure-to-procedure coding combination edits and medically unlikely edits), Current Procedural Technology guidance published by the American Medical Association (AMA) for reporting medical procedures and services, health plan clinical policies based on the appropriateness of health care and medical necessity, and at times state-specific claims reimbursement guidance.
All policies found in the Ambetter of Tennessee Payment Policy Manual apply with respect to Ambetter of Tennessee members. Policies in the Ambetter of Tennessee Payment Policy Manual may have either a Ambetter of Tennessee or a “Centene” heading. In addition, Ambetter of Tennessee may from time to time employ a vendor that applies payment policies to specific services; in such circumstances, the vendor’s guidelines may also be used to determine whether a service has been correctly coded. Other policies (e.g., clinical policies) or contract terms may further determine whether a technology, procedure or treatment that is not addressed in the Payment Policy Manual is payable by Ambetter of Tennessee
If you have any questions regarding these policies, please contact Member Services and ask to be directed to the Medical Management department.
Pharmacy Policies
- Abaloparatide (Tymlos) (CP.PHAR.345) (PDF)
- Abemaciclib (Verzenio) (CP.PHAR.355) (PDF)
- Abiraterone (Zytiga, Yonsa) (CP.PHAR.84) (PDF)
- AbobotulinumtoxinA (Dysport) (CP.PHAR.230) (PDF) Effective Date: 8/1/2025
- Abrocitinib (Cibinqo) (CP.PHAR.578) (PDF)
- Acalabrutinib (Calquence) (CP.PHAR.366) (PDF)
- Acoramidis (Attruby) (CP.PHAR.683) (PDF) Effective Date: 2/1/2025
- Acyclovir Buccal Tablet (Sitavig) (CP.PMN.210) (PDF)
- Adagrasib (Krazati) (CP.PHAR.605) (PDF)
- ADAMTS13, Recombinant-krhn (Adzynma) (CP.PHAR.635) (PDF)
- Adefovir (Hepsera) (CP.PHAR.142) (PDF)
- Ado-Trastuzumab Emtansine (Kadcyla) (CP.PHAR.229) (PDF) Effective Date: 8/1/2025
- Aducanumab-avwa (Aduhelm) (CP.PHAR.468) (PDF)
- Afamelanotide (Scenesse) (CP.PHAR.444) (PDF)
- Afamitresgene Autoleucel (Tecelra) (CP.PHAR.678) (PDF)
- Afatinib (Gilotrif) (CP.PHAR.298) (PDF)
- Aflibercept (Eylea, Eylea HD), Aflibercept-yszy (Opuviz), Aflibercept-jbvf (Yesafili), Aflibercept-mrbb (Ahzantive) (CP.PHAR.184) (PDF)
- Agalsidase Beta (Fabrazyme) (PDF)
- Age Limit Override (Codeine, Tramadol, Hydrocodone) (CP.PMN.138) (PDF)
- Alectinib (Alecensa) (CP.PHAR.369) (PDF) Effective Date: 8/1/2025
- Alemtuzumab (Lemtrada) (CP.PHAR.243) (PDF) Effective Date: 8/1/2025
- Alendronate (Binosto, Fosamax Plus D) (CP.PMN.88) (PDF)
- Alglucosidase Alfa (Lumizyme) (CP.PHAR.160) (PDF)
- Allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen-dsat (StrataGraft) (CP.PHAR.562) (PDF)
- Allogenic Processed Thymus Tissue-agdc (Rethymic) (CP.PHAR.563) (PDF)
- Alpelisib (Piqray, Vijoice) (CP.PHAR.430) (PDF)
- Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) (CP.PHAR.94) (PDF)
- Amantadine ER (Gocovri, Osmolex ER) (CP.PMN.89) (PDF)
- Ambrisentan (Letairis) (CP.PHAR.190) (PDF)
- Amifampridine (Firdapse) (CP.PHAR.411) (PDF)
- Amikacin (Arikayce) (CP.PHAR.401) (PDF)
- Amisulpride (Barhemsys) (CP.PMN.236) (PDF)
- Amivantamab-vmjw (Rybrevant) (CP.PHAR.544) (PDF)
- Anifrolumab-fnia (Saphnelo) (CP.PHAR.551) (PDF)
- Anti-Inhibitor Coagulant Complex, Human (Feiba) (CP.PHAR.217) (PDF)
- Antithrombin III (ATryn, Thrombate III) (CP.PHAR.564) (PDF)
- Antithymocyte Globulin (Atgam, Thymoglobulin) (CP.PHAR.506) (PDF) Effective Date: 8/1/2025
- Apalutamide (Erleada) (CP.PCH.45) (PDF) Effective Date: 8/1/2025
- Apomorphine (Apokyn) (CP.PHAR.488) (PDF)
- Aprepitant (Aponvie, Emend, Cinvanti), Fosaprepitant (Emend for injection, Focinvez) (CP.PMN.19) (PDF)
- Aprocitentan (Tryvio) (CP.PHAR.676) (PDF)
- Aripiprazole Long-Acting Injections (Abilify Maintena, Abilify Asimtufii, Aristada, Aristada Initio) (CP.PHAR.290) (PDF)
- Aripiprazole Orally Disintegrating Tablet (CP.PCH.37) (PDF)
- Armodafinil (Nuvigil) (CP.PMN.35) (PDF)
- Asciminib (Scemblix) (CP.PHAR.565) (PDF)
- Asenapine (Saphris, Secuado) (CP.PMN.15) (PDF)
- Asfotase Alfa (Strensiq) (CP.PHAR.328) (PDF)
- Aspirin/Dipyridamole (Aggrenox) (CP.PMN.20) (PDF)
- Atezolizumab (Tecentriq) (CP.PHAR.235) (PDF)
- Atidarsagene Autotemcel (Lenmeldy) (CP.PHAR.602) (PDF)
- Atogepant (Qulipta) (CP.PHAR.566) (PDF)
- Avacincaptad Pegol (Izervay) (CP.PHAR.641) (PDF)
- Avacopan (Tavneos) (CP.PHAR.515) (PDF)
- Avalglucosidase Alfa-ngpt (Nexviazyme) (CP.PHAR.521) (PDF)
- Avapritinib (Ayvakit) (CP.PHAR.454) (PDF)
- Avatrombopag (Doptelet) (CP.PHAR.130) (PDF)
- Avelumab (Bavencio) (CP.PHAR.333) (PDF)
- Axatilimab-csfr (Niktimvo) (CP.PHAR.691) (PDF)
- Axicabtagene Ciloleucel (Yescarta) (CP.PHAR.362) (PDF)
- Axitinib (Inlyta) (CP.PHAR.100) (PDF)
- Azacitidine (Onureg, Vidaza) (CP.PHAR.387) (PDF)
- Azelaic Acid (Finacea Topical Gel/Foam) (HIM.PA.119) (PDF)
- Aztreonam (Cayston) (CP.PHAR.209) (PDF)
- Baclofen (Fleqsuvy, Gablofen, Lioresal, Lyvispah, Ozobax/Ozobax DS) (CP.PHAR.149) (PDF)
- Baloxavir Marboxil (Xofluza) (CP.PMN.185) (PDF)
- Bedaquiline (Sirturo) (CP.PMN.212) (PDF)
- Belatacept (Nulojix) (CP.PHAR.201) (PDF)
- Belimumab (Benlysta) (CP.PHAR.88) (PDF)
- Belinostat (Beleodaq) (CP.PHAR.311) (PDF)
- Belumosudil (Rezurock) (CP.PHAR.552) (PDF)
- Belzutifan (Welireg) (CP.PHAR.553) (PDF)
- Bempedoic Acid (Nexletol), Bempedoic Acid/Ezetimibe (Nexlizet) (CP.PMN.237) (PDF)
- Bendamustine (Belrapzo, Bendeka, Treanda, Vivimusta) (CP.PHAR.307) (PDF)
- Benralizumab (Fasenra) (HIM.PA.SP70) (PDF)
- Benznidazole (CP.PMN.90) (PDF)
- Berdazimer (Zelsuvmi) (CP.PMN.293) (PDF)
- Beremagene geperpavec-svdt (Vyjuvek) (CP.PHAR.592) (PDF)
- Berotralstat (Orladeyo) (HIM.PA.169) (PDF)
- Betaine (Cystadane) (CP.PHAR.143) (PDF)
- Betamethasone Dipropionate Spray (Sernivo) (CP.PMN.182) (PDF)
- Betibeglogene Autotemcel (Zynteglo) (CP.PHAR.545) (PDF)
- Bevacizumab (Alymsys, Avastin, Avzivi, Mvasi, Vegzelma, Zirabev) (CP.PHAR.93) (PDF)
- Bexarotene (Targretin Capsules, Gel) (CP.PHAR.75) (PDF)
- Bezlotoxumab (Zinplava) (CP.PHAR.300) (PDF)
- Bimatoprost Implant (Durysta) (CP.PHAR.486) (PDF)
- Binimetinib (Mektovi) (CP.PHAR.50) (PDF)
- Biologic and Non-biologic DMARDs (HIM.PA.SP60) (PDF) Effective Date: 8/1/2025
- Birch Triterpenes (Filsuvez) (CP.PHAR.669) (PDF)
- Blinatumomab (Blincyto) (CP.PHAR.312) (PDF)
- Bortezomib (Velcade) (CP.PHAR.410) (PDF)
- Bosentan (Tracleer) (CP.PHAR.191) (PDF)
- Bosutinib (Bosulif) (CP.PHAR.105) (PDF)
- Brand Name Override and Non-Formulary Medications (HIM.PA.103) (PDF)
- Brentuximab Vedotin (Adcetris) (CP.PHAR.303) (PDF)
- Brexanolone (Zulresso) (CP.PHAR.417) (PDF)
- Brexpiprazole (Rexulti) (CP.PMN.68) (PDF)
- Brexucabtagene Autoleucel (Tecartus) (CP.PHAR.472) (PDF)
- Brigatinib (Alunbrig) (CP.PHAR.342) (PDF)
- Brimonidine Tartrate (Mirvaso) (CP.PMN.192) (PDF)
- Brinzolamide/Brimonidine (Simbrinza) (HIM.PA.15) (PDF)
- Brivaracetam (Briviact) (CP.PMN.297) (PDF)
- Brolucizumab-dbll (Beovu) (CP.PHAR.445) (PDF)
- Budesonide (Eohilia, Uceris) (CP.PMN.294) (PDF)
- Budesonide (Tarpeyo) (CP.PHAR.572) (PDF)
- Buprenorphine (Subutex) (CP.PMN.82) (PDF)
- Buprenorphine Injection (Sublocade, Brixadi) (CP.PHAR.289) (PDF)
- Buprenorphine/Naloxone (Suboxone, Zubsolv) (CP.PMN.81) (PDF)
- Bupropion/Naltrexone (Contrave) (CP.PCH.12) (PDF)
- Burosumab-twza (Crysvita) (CP.PHAR.11) (PDF)
- Butorphanol Nasal Spray (HIM.PA.46) (PDF) Effective Date: 8/1/2025
- C1 Esterase Inhibitors (Berinert, Cinryze, Haegarda, Ruconest) (HIM.PA.170) (PDF)
- Cabazitaxel (Jevtana) (CP.PHAR.316) (PDF) Effective Date: 8/1/2025
- Cabotegravir (Apretude), Cabotegravir/Rilpivirine (Cabenuva) (CP.PHAR.573) (PDF)
- Cabozantinib (Cabometyx, Cometriq) (CP.PHAR.111) (PDF)
- Calcifediol (Rayaldee) (CP.PMN.76) (PDF)
- Calcipotriene/Betamethasone Dipropionate Foam (Enstilar) (CP.PMN.181) (PDF)
- Canakinumab (Ilaris) (CP.PHAR.246) (PDF) Effective Date: 8/1/2025
- Cannabidiol (Epidiolex) (CP.PMN.164) (PDF)
- Capecitabine (Xeloda) (CP.PHAR.60) (PDF) Effective Date: 8/1/2025
- Capivasertib (Truqap) (CP.PHAR.663) (PDF)
- Caplacizumab-yhdp (Cablivi) (CP.PHAR.416) (PDF)
- Capmatinib (Tabrecta) (CP.PHAR.494) (PDF)
- Carbidopa/Levodopa ER Capsules (Rytary), Enteral Suspension (Duopa), IR Tablets (Dhivy) (CP.PMN.238) (PDF)
- Carfilzomib (Kyprolis) (CP.PHAR.309) (PDF)
- Carglumic Acid (Carbaglu) (CP.PHAR.206) (PDF)
- Cariprazine (Vraylar) (CP.PMN.91) (PDF)
- Casimersen (Amondys 45) (CP.PHAR.470) (PDF)
- Celecoxib (Celebrex, Elyxyb) (CP.PMN.122) (PDF)
- Cemiplimab-rwlc (Libtayo) (CP.PHAR.397) (PDF)
- Cenegermin-bkbj (Oxervate) (CP.PMN.186) (PDF)
- Cenobamate (Xcopri) (CP.PMN.231) (PDF)
- Ceritinib (Zykadia) (CP.PHAR.349) (PDF) Effective Date: 8/1/2025
- Cerliponase Alfa (Brineura) (CP.PHAR.338) (PDF)
- Cetuximab (Erbitux) (CP.PHAR.317) (PDF)
- Chenodiol (Chenodal) (CP.PMN.239) (PDF)
- Chlorambucil (Leukeran) (CP.PHAR.554) (PDF)
- Chloramphenicol Sodium Succinate (CP.PHAR.388) (PDF)
- Cholic Acid (Cholbam) (CP.PHAR.390) (PDF)
- Ciclopirox Topical Solution 8% (PDF)
- Ciltacabtagene Autoleucel (Carvykti) (CP.PHAR.533) (PDF)
- Cinacalcet (Sensipar) (CP.PHAR.61) (PDF)
- Cipaglucosidase Alfa-atga + Miglustat (Pombiliti + Opfolda) (CP.PHAR.567) (PDF)
- Ciprofloxacin/Dexamethasone (Ciprodex) (CP.PMN.248) (PDF)
- Ciprofloxacin/Fluocinolone (Otovel) (CP.PMN.249) (PDF)
- Cladribine (Mavenclad) (CP.PHAR.422) (PDF) Effective Date: 8/1/2025
- Clascoterone (Winlevi) (CP.PMN.257) (PDF)
- Clobazam (Onfi, Sympazan) (CP.PMN.54) (PDF)
- CNS Stimulants (CP.PMN.92) (PDF)
- Cobimetinib (Cotellic) (CP.PHAR.380) (PDF) Effective Date: 8/1/2025
- Colchicine (Colcrys, Lodoco) (CP.PMN.123) (PDF)
- Colesevelam (Welchol) (CP.PMN.250) (PDF)
- Collagenase Clostridium Histolyticum (Xiaflex) (CP.PHAR.82) (PDF)
- Colonoscopy Preparation Products (CP.PCH.43) (PDF)
- Compounded Medications (CP.PMN.280) (PDF)
- Concizumab-tci (Alhemo) (CP.PHAR.625) (PDF) Effective Date: 8/1/2025
- Conjugated Estrogens/Bazedoxifene (Duavee) (CP.PMN.258) (PDF)
- Continuous Glucose Monitors (CP.PMN.214) (PDF)
- Copanlisib (Aliqopa) (CP.PHAR.357) (PDF)
- Corticosteroids for Ophthalmic Injection (Dextenza, Iluvien, Ozurdex, Retisert, Xipere, Yutiq) (CP.PHAR.385) (PDF)
- Cosibelimab-lpdl (Unloxcyt) (CP.PHAR.711) (PDF) Effective Date: 3/1/2025
- Cosyntropin (Cortrosyn) (CP.PHAR.203) (PDF)
- Crinecerfont (Crenessity) (CP.PHAR.692) (PDF) Effective Date: 2/1/2025
- Crisaborole (Eucrisa) (CP.PMN.110) (PDF)
- Crizanlizumab-tmca (Adakveo) (CP.PHAR.449) (PDF)
- Crizotinib (Xalkori) (CP.PHAR.90) (PDF) Effective Date: 8/1/2025
- Crovalimab-akkz (PiaSky) (CP.PHAR.664) (PDF)
- Cyclosporine (Cequa, Restasis, Verkazia, Vevye, Klarity-C) (CP.PMN.48) (PDF)
- Cysteamine Ophthalmic (Cystaran, Cystadrops) (CP.PMN.130) (PDF)
- Cysteamine oral (Cystagon, Procysbi) (CP.PHAR.155) (PDF) Effective Date: 8/1/2025
- Cytomegalovirus Immune Globulin (CytoGam) (CP.PHAR.277) (PDF)
- Dabrafenib (Tafinlar) (CP.PHAR.239) (PDF) Effective Date: 8/1/2025
- Dacomitinib (Vizimpro) (CP.PHAR.399) (PDF)
- Dalfampridine (Ampyra) (CP.PHAR.248) (PDF)
- Dalteparin (Fragmin) (CP.PHAR.225) (PDF)
- Danicopan (Voydeya) (CP.PHAR.665) (PDF)
- Dapsone (Aczone Gel) (CP.PCH.32) (PDF)
- Daptomycin (Cubicin, Cubicin RF, Dapzura RT) (CP.PHAR.351) (PDF)
- Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro) (CP.PHAR.310) (PDF)
- Darbepoetin Alfa (Aranesp) (CP.PHAR.236) (PDF) Effective Date: 8/1/2025
- Darolutamide (Nubeqa) (CP.PHAR.435) (PDF)
- Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira Pak) (HIM.PA.SP61) (PDF)
- Dasatinib (Sprycel, Phyrago) (CP.PHAR.72) (PDF)
- Datopotamab Deruxtecan-dlnk (Datroway) (CP.PHAR.715) (PDF)
- Daunorubicin/Cytarabine (Vyxeos) (CP.PHAR.352) (PDF)
- DaxibotulinumtoxinA-lanm (Daxxify) (CP.PHAR.651) (PDF)
- Decitabine/Cedazuridine (Inqovi) (CP.PHAR.479) (PDF)
- Deferasirox (Exjade, Jadenu) (CP.PHAR.145) (PDF)
- Deferoxamine (Desferal) (CP.PHAR.146) (PDF)
- Deflazacort (Emflaza) (CP.PHAR.331) (PDF)
- Degarelix Acetate (Firmagon) (CP.PHAR.170) (PDF)
- Delafloxacin (Baxdela) (CP.PMN.115) (PDF)
- Delandistrogene Moxeparvovec-rokl (Elevidys) (CP.PHAR.593) (PDF)
- Denileukin Diftitox-cxdl (Lymphir) (CP.PHAR.693) (PDF)
- Denosumab (Prolia, Xgeva), Denosumab-bbdz (Jubbonti, Wyost) (CP.PHAR.58) (PDF)
- Desmopressin Acetate (DDAVP, Stimate, Nocdurna) (CP.PHAR.214) (PDF)
- Deutetrabenazine (Austedo, Austedo XR) (CP.PCH.42) (PDF)
- Dexrazoxane (Totect) (CP.PHAR.418) (PDF) Effective Date: 8/1/2025
- Dextromethorphan/Bupropion (Auvelity) (CP.PMN.284) (PDF)
- Dextromethorphan-Quinidine (Nuedexta) (CP.PMN.93) (PDF)
- Diazepam (Libervant, Valtoco) (CP.PMN.216) (PDF)
- Dichlorphenamide (Keveyis) (CP.PMN.261) (PDF)
- Diclofenac (Cambia, Flector, Licart, Pennsaid, Solaraze, Zipsor, Zorvolex) (CP.PCH.28) (PDF)
- Dimethyl Fumarate (Tecfidera), Diroximel Fumarate (Vumerity), Monomethyl Fumarate (Bafiertam) (CP.PHAR.249) (PDF) Effective Date: 8/1/2025
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (HIM.PA.58) (PDF)
- Dolasetron (Anzemet) (CP.PMN.141) (PDF)
- Donanemab (Kinsunla) (CP.PHAR.594) (PDF)
- Dornase Alfa (Pulmozyme) (CP.PHAR.212) (PDF)
- Dostarlimab-gxly (Jemperli) (CP.PHAR.540) (PDF)
- Doxepin (Silenor, Prudoxin, Zonalon) (HIM.PA.147) (PDF)
- Doxycycline Hyclate (Acticlate, Doryx), Doxycycline (Oracea) (CP.PMN.79) (PDF)
- Dupilumab (Dupixent) (HIM.PA.SP69) (PDF)
- Durvalumab (Imfinzi) (CP.PHAR.339) (PDF) Effective Date: 8/1/2025
- Dutasteride (Avodart), Dutasteride/Tamsulosin (Jalyn) (CP.PMN.128) (PDF)
- Duvelisib (Copiktra) (CP.PHAR.400) (PDF)
- Ecallantide (Kalbitor) (CP.PHAR.177) (PDF)
- Eculizumab (Soliris) (CP.PHAR.97) (PDF)
- Edaravone (Radicava, Radivaca ORS) (CP.PHAR.343) (PDF) Effective Date: 8/1/2025
- Efgartigimod Alfa-fcab, Efgartigimod/Hyaluronidase-qvfc (Vyvgart, Vyvgart Hytrulo) (CP.PHAR.555) (PDF)
- Efinaconazole (Jublia) (CP.PMN.25) (PDF)
- Eflornithine (Iwilfin) (CP.PHAR.670) (PDF)
- Elacestrant (Orserdu) (CP.PHAR.623) (PDF)
- Eladocagene Exuparvovec-tneq (Kebilidi) (CP.PHAR.595) (PDF) Effective Date: 3/1/2025
- Elafibranor (Iqirvo) (CP.PHAR.688) (PDF)
- Elagolix (Orilissa), Elagolix/Estradiol/Norethinedrone (Oriahnn) (CP.PHAR.136) (PDF)
- Elapegademase-lvlr (Revcovi) (CP.PHAR.419) (PDF) Effective Date: 8/1/2025
- Elbasvir/Grazoprevir (Zepatier) (HIM.PA.SP62) (PDF)
- Elexacaftor/Ivacaftor/Tezacaftor; Ivacaftor (Trikafta) (CP.PHAR.440) (PDF)
- Eliglustat (Cerdelga) (CP.PHAR.153) (PDF)
- Elivaldogene Autotemcel (Skysona) (CP.PHAR.556) (PDF)
- Elosulfase Alfa (Vimizim) (CP.PHAR.162) (PDF)
- Elotuzumab (Empliciti) (CP.PHAR.308) (PDF)
- Elranatamab-bcmm (Elrexfio) (CP.PHAR.652) (PDF)
- Eltrombopag (Alvaiz, Promacta) (CP.PHAR.180) (PDF)
- Eluxadoline (Viberzi) (CP.PMN.170) (PDF)
- Emapalumab-lzsg (Gamifant) (CP.PHAR.402) (PDF)
- Emicizumab-kxwh (Hemlibra) (CP.PHAR.370) (PDF)
- Emtricitabine/Tenofovir Alafenamide (Descovy) (CP.PMN.235) (PDF)
- Enasidenib (Idhifa) (CP.PHAR.363) (PDF)
- Encorafenib (Braftovi) (CP.PHAR.127) (PDF)
- Enfortumab Vedotin-ejfv (Padcev) (CP.PHAR.455) (PDF)
- Enfuvirtide (Fuzeon) (CP.PHAR.41) (PDF)
- Enoxaparin (Lovenox) (CP.PHAR.224) (PDF)
- Ensartinib (Ensacove) (CP.PHAR.712) (PDF) Effective Date: 3/1/2025
- Entecavir (Baraclude) (HIM.PA.08) (PDF) Effective Date: 8/1/2025
- Entrectinib (Rozlytrek) (CP.PHAR.441) (PDF)
- Enzalutamide (Xtandi) (CP.PHAR.106) (PDF)
- Epcoritamab-bysp (Epkinly) (CP.PHAR.634) (PDF)
- Epinephrine (EpiPen, EpiPen Jr, Auvi-Q, Neffy) (CP.PCH.55) (PDF) Effective Date: 8/1/2025
- Eplontersen (Wainua) (CP.PHAR.633) (PDF) Effective Date: 8/1/2025
- Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) (CP.PHAR.237) (PDF) Effective Date: 8/1/2025
- Epoprostenol (Flolan, Veletri) (CP.PHAR.192) (PDF)
- Eptinezumab-jjmr (Vyepti) (HIM.PA.SP64) (PDF)
- Erdafitinib (Balversa) (CP.PHAR.423) (PDF)
- Erenumab-aooe (Aimovig) (HIM.PA.SP65) (PDF)
- Eribulin Mesylate (Halaven) (CP.PHAR.318) (PDF)
- Erlotinib (Tarceva) (CP.PHAR.74) (PDF)
- Erwinia Asparaginase (Rylaze) (CP.PHAR.301) (PDF)
- Esketamine (Spravato) (CP.PMN.199) (PDF) Effective Date: 8/1/2025
- Estradiol Vaginal Ring (Femring) (CP.PMN.263) (PDF)
- Etelcalcetide (Parsabiv) (CP.PHAR.379) (PDF)
- Eteplirsen (Exondys 51) (CP.PHAR.288) (PDF)
- Etranacogene Dezaparvovec-drlb (Hemgenix) (CP.PHAR.580) (PDF)
- Everolimus (Afinitor, Afinitor Disperz, Zortress) (CP.PHAR.63) (PDF)
- Evinacumab-dgnb (Evkeeza) (HIM.PA.166) (PDF)
- Evolocumab (Repatha) (HIM.PA.156) (PDF)
- Exagamglogene Autotemcel (Casgevy) (CP.PHAR.603) (PDF)
- Factor IX (Human, Recombinant) (CP.PHAR.218) (PDF)
- Factor IX Complex, Human (Profilnine) (CP.PHAR.219) (PDF)
- Factor VIIa, Recombinant (NovoSeven RT, SevenFact) (CP.PHAR.220) (PDF)
- Factor VIII (Human, Recombinant) (CP.PHAR.215) (PDF)
- Factor VIII/von Willebrand Factor Complex (Human – Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant – Vonvendi) (CP.PHAR.216) (PDF)
- Factor XIII A-Subunit, Recombinant (Tretten) (CP.PHAR.222) (PDF)
- Factor XIII, Human (Corifact) (CP.PHAR.221) (PDF)
- Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (CP.PHAR.456) (PDF)
- Faricimab-svoa (Vabysmo) (CP.PHAR.581) (PDF)
- Febuxostat (Uloric) (CP.PMN.57) (PDF)
- Fecal Microbiota Spores, Live-brpk (Vowst) (CP.PHAR.632) (PDF)
- Fecal Microbiota, Live-jslm (Rebyota) (CP.PHAR.613) (PDF)
- Fedratinib (Inrebic) (CP.PHAR.442) (PDF)
- Fenfluramine (Fintepla) (CP.PMN.246) (PDF)
- Fentanyl IR (Actiq, Fentora, Lazanda, Subsys) (CP.PMN.127) (PDF)
- Ferric Carboxymaltose (Injectafer) (CP.PHAR.234) (PDF)
- Ferric Derisomaltose (Monoferric) (CP.PHAR.480) (PDF)
- Ferric Maltol (Accrufer) (CP.PMN.213) (PDF)
- Ferumoxytol (Feraheme) (CP.PHAR.165) (PDF)
- Fezolinetant (Veozah) (CP.PMN.289) (PDF)
- Fibrinogen Concentrate [Human] (Fibryga, RiaSTAP) (CP.PHAR.526) (PDF)
- Fidanacogene Elaparvovec-dzkt (Beqvez) (CP.PHAR.643) (PDF)
- Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix), Filgrastim-aafi (Nivestym), Filgrastim-ayow (Releuko), Filgrastim-txid (Nypozi) (CP.PHAR.297) (PDF)
- Finerenone (Kerendia) (CP.PMN.266) (PDF)
- Fitusiran (Qfitlia) (CP.PHAR.706) (PDF)
- Flibanserin (Addyi) (CP.PHAR.446) (PDF)
- Fluorouracil Cream (Tolak) (CP.PMN.165) (PDF)
- Fluticasone Propionate (Xhance) (CP.PMN.95) (PDF)
- Fondaparinux (Arixtra) (CP.PHAR.226) (PDF)
- Fosdenopterin (Nulibry) (CP.PHAR.471) (PDF)
- Fostamatinib (Tavalisse) (CP.PHAR.24) (PDF)
- Fostemsavir (Rukobia) (CP.PHAR.516) (PDF)
- Fremanezumab-vfrm (Ajovy) (HIM.PA.SP66) (PDF)
- Fruquintinib (Fruzaqla) (CP.PHAR.666) (PDF)
- Fulvestrant (Faslodex Injection) (CP.PHAR.424) (PDF)
- Furosemide (Furoscix) (CP.PHAR.608) (PDF)
- Futibatinib (Lytgobi) (CP.PHAR.604) (PDF)
- Gabapentin ER (Gralise, Horizant) (CP.PMN.240) (PDF)
- Galcanezumab-gnlm (Emgality) (HIM.PA.SP67) (PDF)
- Galsulfase (Naglazyme) (CP.PHAR.161) (PDF)
- Ganaxolone (Ztalmy) (CP.PMN.278) (PDF)
- Gefitinib (Iressa) (CP.PHAR.68) (PDF)
- Gemtuzumab Ozogamicin (Mylotarg) (CP.PHAR.358) (PDF)
- Gilteritinib (Xospata) (CP.PHAR.412) (PDF)
- Givinostat (Duvyzat) (CP.PHAR.644) (PDF)
- Givosiran (Givlaari) (CP.PHAR.457) (PDF)
- Glasdegib (Daurismo) (CP.PHAR.413) (PDF)
- Glatiramer Acetate (Copaxone, Glatopa) (CP.PHAR.252) (PDF) Effective Date: 8/1/2025
- Glaucoma Agents (CP.PMN.286) (PDF)
- Glecaprevir/Pibrentasvir (Mavyret) (HIM.PA.SP36) (PDF)
- Glofitamab-gxbm (Columvi) (CP.PHAR.636) (PDF)
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (HIM.PA.53) (PDF)
- Glycerol Phenylbutyrate (Ravicti) (CP.PHAR.207) (PDF)
- Golodirsen (Vyondys 53) (CP.PHAR.453) (PDF)
- Goserelin Acetate (Zoladex) (CP.PHAR.171) (PDF)
- Granisetron (Sancuso, Sustol) (CP.PMN.74) (PDF)
- Halcinonide (Halog) (HIM.PA.20) (PDF)
- Halobetasol Propionate (Bryhali, Lexette, Ultravate) (CP.PMN.180) (PDF)
- Halobetasol Propionate/Tazarotene (Duobrii) (CP.PMN.208) (PDF)
- Hemin (Panhematin) (CP.PHAR.181) (PDF)
- Histrelin Acetate (Vantas, Supprelin LA) (CP.PHAR.172) (PDF)
- House Dust Mite Allergen Extract (Odactra) (CP.PMN.111) (PDF)
- Human Growth Hormone (Somapacitan, Somatrogon, Somatropin) (HIM.PA.161) (PDF)
- Hyaluronate Derivatives (CP.PHAR.05) (PDF)
- Hydroxyurea (Siklos, Xromi) (CP.PMN.193) (PDF)
- Ibalizumab-uiyk (Trogarzo) (CP.PHAR.378) (PDF)
- Ibandronate Injection (Boniva) (CP.PHAR.189) (PDF)
- Ibrutinib (Imbruvica) (CP.PHAR.126) (PDF)
- Ibuprofen/Famotidine (Duexis) (CP.PMN.120) (PDF)
- Icatibant (Firazyr) (CP.PHAR.178) (PDF)
- Icosapent Ethyl (Vascepa) (CP.PMN.187) (PDF)
- Idecabtagene Vicleucel (Abecma) (CP.PHAR.481) (PDF)
- Idelalisib (Zydelig) (CP.PHAR.133) (PDF)
- Idursulfase (Elaprase) (CP.PHAR.156) (PDF)
- Iloperidone (Fanapt) (CP.PMN.32) (PDF)
- Iloprost (Ventavis) (CP.PHAR.193) (PDF)
- Imatinib (Gleevec) (CP.PHAR.65) (PDF)
- Imetelstat (Rytelo) (CP.PHAR.690) (PDF)
- Imiglucerase (Cerezyme) (CP.PHAR.154) (PDF)
- Immune Globulins (CP.PHAR.103) (PDF) Effective Date: 8/1/2025
- Inavolisib (Itovebi) (CP.PHAR.702) (PDF)
- Inclisiran (Leqvio) (CP.PHAR.568) (PDF)
- IncobotulinumtoxinA (Xeomin) (CP.PHAR.231) (PDF) Effective Date: 8/1/2025
- Inebilizumab-cdon (Uplizna) (CP.PHAR.458) (PDF)
- Infertility and Fertility Preservation (CP.PHAR.131) (PDF)
- Infigratinib (Truseltiq) (CP.PHAR.547) (PDF)
- Inhaled Agents for Asthma and COPD (HIM.PA.153) (PDF)
- Inotersen (Tegsedi) (CP.PHAR.405) (PDF) Effective Date: 8/1/2025
- Inotuzumab Ozogamicin (Besponsa) Reference Number: CP.PHAR.359 Effective Date: 09.26.17 Last Review Date: 11.24 Line of Business: Commercial, HIM, Medicaid (CP.PHAR.359) (PDF)
- Insulin Delivery Systems (V-Go, Omnipod, InPen) (CP.PHAR.534) (PDF)
- Insulin detemir (Levemir) (HIM.PA.171) (PDF)
- Insulin Glargine (Rezvoglar, Semglee, Toujeo) (HIM.PA.09) (PDF)
- Interferon Beta-1a (Avonex, Rebif) (CP.PHAR.255) (PDF) Effective Date: 8/1/2025
- Interferon Beta-1b (Betaseron, Extavia) (CP.PCH.46) (PDF) Effective Date: 8/1/2025
- Interferon Gamma- 1b (Actimmune) (CP.PHAR.52) (PDF)
- Iobenguane I-131 (Azedra) (CP.PHAR.459) (PDF)
- Ipilimumab (Yervoy) (CP.PHAR.319) (PDF) Effective Date: 8/1/2025
- Iptacopan (Fabhalta) (CP.PHAR.656) (PDF)
- Irinotecan Liposome (Onivyde) (CP.PHAR.304) (PDF)
- Isatuximab-irfc (Sarclisa) (CP.PHAR.482) (PDF) Effective Date: 8/1/2025
- Isavuconazonium (Cresemba) (CP.PMN.154) (PDF)
- Isotretinoin (Absorica, Absorica LD, Amnesteem, Claravis, Myorisan, Zenatane) (CP.PMN.143) (PDF)
- Istradefylline (Nourianz) (CP.PMN.217) (PDF)
- Itraconazole (Sporanox, Tolsura) (CP.PMN.124) (PDF)
- Ivabradine (Corlanor) (CP.PMN.70) (PDF)
- Ivacaftor (Kalydeco) (CP.PHAR.210) (PDF)
- Ivermectin (Stromectol, Sklice) (CP.PMN.269) (PDF)
- Ivosidenib (Tibsovo) (CP.PHAR.137) (PDF)
- Ixazomib (Ninlaro) (CP.PHAR.302) (PDF)
- Ketamine (Ketalar) (CP.PMN.296) (PDF)
- Ketorolac Nasal Spray (Sprix) (CP.PMN.282) (PDF)
- Lanadelumab-fylo (Takhzyro) (HIM.PA.172) (PDF)
- Lanreotide (Somatuline Depot and Unbranded) (CP.PHAR.391) (PDF)
- Lapatinib (Tykerb) (CP.PHAR.79) (PDF)
- Laronidase (Aldurazyme) Reference Number: CP.PHAR.152 Effective Date: 02.01.16 Last Review Date: 05.24 Line of Business: Commercial, HIM, Medicaid (CP.PHAR.152) (PDF)
- Larotrectinib (Vitrakvi) (CP.PHAR.414) (PDF)
- Lasmiditan (Reyvow) (CP.PMN.218) (PDF)
- Lazertinib (Lazcluze) (CP.PHAR.695) (PDF)
- Lecanemab-irmb (Leqembi) (CP.PHAR.596) (PDF)
- Ledipasvir/Sofosbuvir (Harvoni) (HIM.PA.SP3) (PDF)
- Lefamulin (Xenleta) (CP.PMN.219) (PDF)
- Lenacapavir (Sunlenca) (CP.PHAR.622) (PDF)
- Lenalidomide (Revlimid) (CP.PHAR.71) (PDF) Effective Date: 8/1/2025
- Leniolisib (Joenja) (CP.PHAR.597) (PDF)
- Lenvatinib (Lenvima) (CP.PHAR.138) (PDF)
- Letermovir (Prevymis) (CP.PHAR.367) (PDF)
- Leucovorin Injection (CP.PHAR.393) (PDF)
- Leuprolide Acetate (Eligard, Fensolvi, Lupron Depot, Lupron Depot-Ped), Leuprolide mesylate (Camcevi) (CP.PCH.53) (PDF)
- Levacetylleucine (Aqneursa) (CP.PHAR.682) (PDF)
- Levodopa Inhalation Powder (Inbrija) (CP.PMN.267) (PDF)
- Levoketoconazole (Recorlev) (CP.PMN.275) (PDF)
- Levoleucovorin (Fusilev, Khapzory) (CP.PHAR.151) (PDF)
- Levomilnacipran (Fetzima) (HIM.PA.125) (PDF)
- L-glutamine (Endari) (CP.PMN.116) (PDF)
- Lidocaine Transdermal (Lidoderm, ZTlido) (CP.PMN.08) (PDF)
- Lifileucel (Amtagvi) (CP.PHAR.598) (PDF)
- Lifitegrast (Xiidra) (CP.PMN.73) (PDF)
- Linezolid (Zyvox) (CP.PMN.27) (PDF)
- Lisocabtagene Maraleucel (Breyanzi) (CP.PHAR.483) (PDF) Effective Date: 8/1/2025
- Lofexidine (Lucemyra) (CP.PMN.152) (PDF)
- Lomustine (Gleostine) (CP.PHAR.507) (PDF)
- Lonafarnib (Zokinvy) (CP.PHAR.499) (PDF)
- Loncastuximab Tesirine-lpyl (Zynlonta) (CP.PHAR.539) (PDF)
- Long-term Antibiotic Treatment for Tick-borne Diseases (CP.PMN.279) (PDF)
- Lorlatinib (Lorbrena) (CP.PHAR.406) (PDF) Effective Date: 8/1/2025
- Loteprednol etabonate (Eysuvis) (CP.PMN.260) (PDF)
- Lotilaner (Xdemvy) (CP.PMN.291) (PDF)
- Lovotibeglogene Autotemcel (Lyfgenia) (CP.PHAR.627) (PDF)
- Lubiprostone (Amitiza) (CP.PMN.142) (PDF)
- Luliconazole Cream (Luzu) (CP.PMN.166) (PDF)
- Lumacaftor/Ivacaftor (Orkambi) (CP.PHAR.213) (PDF)
- Lumasiran (Oxlumo) (CP.PHAR.473) (PDF)
- Lumateperone (Caplyta) (CP.PMN.232) (PDF)
- Lurbinectedin (Zepzelca) (CP.PHAR.500) (PDF)
- Luspatercept-aamt (Reblozyl) (CP.PHAR.450) (PDF)
- Lusutrombopag (Mulpleta) (CP.PHAR.407) (PDF)
- Lutetium Lu 177 Dotatate (Lutathera) (CP.PHAR.384) (PDF)
- Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) (CP.PHAR.582) (PDF)
- Macitentan (Opsumit) (CP.PHAR.194) (PDF)
- Mannitol (Bronchitol) (CP.PHAR.518) (PDF)
- Maralixibat (Livmarli) (CP.PHAR.543) (PDF)
- Margetuximab-cmkb (Margenza) (CP.PHAR.522) (PDF)
- Maribavir (Livtencity) (CP.PMN.271) (PDF)
- Mavacamten (Camzyos) (CP.PMN.272) (PDF)
- Mavorixafor (Xolremdi) (CP.PHAR.679) (PDF)
- Mecamylamine (Vecamyl) (CP.PMN.136) (PDF)
- Mecasermin (Increlex) (CP.PHAR.150) (PDF)
- Mechlorethamine Gel (Valchlor) (CP.PHAR.381) (PDF)
- Megestrol Acetate (CP.PMN.179) (PDF)
- Melphalan (Hepzato) (CP.PHAR.653) (PDF)
- Memantine ER (Namenda XR), Memantine/Donepezil (Namzaric) (CP.PCH.30) (PDF)
- Mepolizumab (Nucala) (CP.PHAR.200) (PDF)
- Mercaptopurine (Purixan) (CP.PHAR.447) (PDF)
- Metformin ER (Fortamet, Glumetza) (CP.PMN.72) (PDF)
- Methotrexate (Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo) (CP.PHAR.134) (PDF)
- Methoxsalen (Uvadex) (HIM.PA.17) (PDF)
- Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) (CP.PHAR.238) (PDF) Effective Date 8/1/2025
- Methylnaltrexone Bromide (Relistor) (CP.PMN.169) (PDF)
- Metoclopramide (Gimoti) (CP.PMN.252) (PDF)
- Metreleptin (Myalept) (CP.PHAR.425) (PDF)
- Midazolam (Nayzilam) (CP.PMN.211) (PDF)
- Midostaurin (Rydapt) (CP.PHAR.344) (PDF) Effective Date: 8/1/2025
- Mifepristone (Korlym) (CP.PHAR.101) (PDF)
- Migalastat (Galafold) (CP.PHAR.394) (PDF)
- Miglustat (Zavesca) (CP.PHAR.164 ) (PDF)
- Milnacipran (Savella) (CP.PMN.125) (PDF) Effective Date: 8/1/2025
- Minocycline ER (Solodyn, Ximino, Minolira), Microspheres (Arestin), Foam (Zilxi) (CP.PMN.80) (PDF)
- Mirdametinib (Gomekli) (CP.PHAR.718) (PDF)
- Mirvetuximab soravatansine-gynx (Elahere) (CP.PHAR.617) (PDF)
- Mitapivat (Pyrukynd) (CP.PHAR.558) (PDF)
- Mitomycin for Pyelocalyceal Solution (Jelmyto) (CP.PHAR.495) (PDF)
- Mitoxantrone (CP.PHAR.258) (PDF) Effective Date: 8/1/2025
- Mobocertinib (Exkivity) (CP.PHAR.559) (PDF)
- Modafinil (Provigil) (CP.PMN.39) (PDF)
- Mogamulizumab-kpkc (Poteligeo) (CP.PHAR.139) (PDF)
- Momelotinib (Ojjaara) (CP.PHAR.654) (PDF)
- Mometasone (Nasonex) (HIM.PA.93) (PDF)
- Mometasone Furoate (Sinuva) (CP.PHAR.448) (PDF)
- Mosunetuzumab-axgb (Lunsumio) (CP.PHAR.618) (PDF)
- Motixafortide (Aphexda) (CP.PHAR.655) (PDF)
- Moxetumomab Pasudotox-tdfk (Lumoxiti) (CP.PHAR.398) (PDF)
- Nabumetone Double-Strength (Relafen DS) (CP.PMN.287) (PDF)
- Nadofaragene Firadenovec-vncg (Adstiladrin) (CP.PHAR.461) (PDF)
- Nafarelin Acetate (Synarel) (CP.PHAR.174) (PDF)
- Naldemedine (Symproic) (CP.PMN.112) (PDF)
- Nalmefene (Opvee) (CP.PHAR.638) (PDF)
- Naloxegol (Movantik) (HIM.PA.167) (PDF)
- Naltrexone (Vivitrol) (CP.PHAR.96) (PDF)
- Naproxen Oral Suspension (Naprosyn) (HIM.PA.130) (PDF)
- Naproxen/Esomeprazole (Vimovo) (CP.PMN.117) (PDF)
- Natalizumab (Tysabri), Natalizumab-sztn (Tyruko) (CP.PHAR.259) (PDF) Effective Date: 8/1/2025
- Naxitamab-gqgk (Danyelza) (CP.PHAR.523) (PDF)
- Necitumumab (Portrazza) (CP.PHAR.320) (PDF)
- Nedosiran (Rivfloza) (CP.PHAR.619) (PDF)
- Nemolizumab-ilto (Nemluvio) (CP.PHAR.703) (PDF)
- Neomycin/Fluocinolone Cream (Neo-Synalar) (CP.PMN.167) (PDF)
- Neratinib (Nerlynx) (CP.PHAR.365) (PDF)
- Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) (CP.PMN.158) (PDF)
- Nifurtimox (Lampit) (CP.PMN.256) (PDF)
- Nilotinib (Tasigna) (CP.PHAR.76) (PDF)
- Nintedanib (Ofev) (CP.PHAR.285) (PDF)
- Niraparib (Zejula) (CP.PHAR.408) (PDF)
- Niraparib and Abiraterone Acetate (Akeega) (CP.PHAR.645) (PDF)
- Nirmatrelvir and Ritonavir (Paxlovid) (CP.PMN.288) (PDF)
- Nirogacestat (Ogsiveo) (CP.PHAR.671) (PDF)
- Nirsevimab-alip (Beyfortus) (CP.PHAR.614) (PDF)
- Nitazoxanide (Alinia) (HIM.PA.152) (PDF)
- Nitisinone (Nityr, Orfadin) (CP.PHAR.132) (PDF)
- Nivolumab (Opdivo) (CP.PHAR.121) (PDF) Effective Date: 8/1/2025
- Nivolumab and Relatlimab-rmbw (Opdualag) (CP.PHAR.588) (PDF)
- No Coverage Criteria, Recent Label Changes Pending Clinical Policy Update (HIM.PA.33) (PDF)
- Nogapendekin Alfa Inbakicept-pmln (Anktiva) (CP.PHAR.684) (PDF)
- Non-Calcium Phosphate Binders (CP.PMN.04) (PDF) Effective Date: 9/1/12025
- Non-Formulary and Formulary Contraceptives (HIM.PA.100) (PDF)
- Non-Formulary Test Strips (HIM.PA.34) (PDF)
- Nusinersen (Spinraza) (CP.PHAR.327) (PDF) Effective Date: 8/1/2025
- Obecabtagene autoleucel (Aucatzyl) (CP.PHAR.675) (PDF) Effective Date: 3/1/2025
- Obeticholic Acid (Ocaliva) (CP.PHAR.287) (PDF)
- Obinutuzumab (Gazyva) (CP.PHAR.305) (PDF)
- Ocrelizumab (Ocrevus) (CP.PHAR.335) (PDF) Effective Date: 8/1/2025
- Octreotide Acetate (Sandostatin, Sandostatin LAR Depot, Mycapssa) (CP.PHAR.40) (PDF)
- Odevixibat (Bylvay) (CP.PHAR.528) (PDF) Effective Date: 8/1/2025
- Ofatumumab (Arzerra, Kesimpta) (CP.PHAR.306) (PDF) Effective Date: 8/1/2025
- Off-Label Drug Use (HIM.PA.154) (PDF)
- Olanzapine Long-Acting Injection (Zyprexa Relprevv) (CP.PHAR.292) (PDF)
- Olanzapine/Samidorphan (Lybalvi) (CP.PMN.265) (PDF)
- Olaparib (Lynparza) (CP.PHAR.360) (PDF)
- Olipudase Alfa-rpcp (Xenpozyme) (CP.PHAR.586) (PDF)
- Olutasidenib (Rezlidhia) (CP.PHAR.615) (PDF)
- Omacetaxine (Synribo) (CP.PHAR.108) (PDF) Effective Date: 8/1/2025
- Omadacycline (Nuzyra) (CP.PMN.188) (PDF)
- Omalizumab (Xolair) (CP.PCH.49) (PDF)
- Omaveloxolone (Skyclarys) (CP.PHAR.590) (PDF)
- OnabotulinumtoxinA (Botox) (CP.PHAR.232) (PDF) Effective Date: 8/1/2025
- Onasemnogene Abeparvovec (Zolgensma) (CP.PHAR.421) (PDF) Effective Date: 8/1/2025
- Ophthalmic Corticosteroids (HIM.PA.03) (PDF)
- Ophthalmic Riboflavin (Photrexa, Photrexa Viscous) (CP.PHAR.536) (PDF)
- Opicapone (Ongentys) (CP.PMN.245) (PDF)
- Opioid Analgesics* (HIM.PA.139) (PDF)
- Osilodrostat (Isturisa) (CP.PHAR.487) (PDF)
- Osimertinib (Tagrisso) (CP.PHAR.294) (PDF)
- Ospemifene (Osphena) (CP.PMN.168) (PDF)
- Overactive Bladder Agents (CP.PMN.198) (PDF) Effective Date: 8/1/2025
- Oxymetazoline (Rhofade, Upneeq) (CP.PMN.86) (PDF)
- Ozanimod (Zeposia) (CP.PHAR.462) (PDF) Effective Date: 8/1/2025
- Ozenoxacin (Xepi) (CP.PMN.119) (PDF)
- Paclitaxel, Protein-Bound (Abraxane) (CP.PHAR.176) (PDF) Effective Date: 8/1/2025
- Pacritinib (Vonjo) (CP.PHAR.583) (PDF) Effective Date: 8/1/2025
- Palbociclib (Ibrance) (HIM.PA.173) (PDF)
- Paliperidone Long-Acting Injections (Invega Hafyera, Invega Sustenna, Invega Trinza) (CP.PHAR.291) (PDF)
- Palivizumab (Synagis) (CP.PHAR.16) (PDF) Effective Date: 8/1/2025
- Palopegteriparatide (Yorvipath) (CP.PHAR.696) (PDF)
- Palovarotene (Sohonos) (CP.PHAR.548) (PDF)
- Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep) (CP.PCH.44) (PDF)
- Panitumumab (Vectibix) (CP.PHAR.321) (PDF)
- Parathyroid Hormone (Natpara) (CP.PHAR.282) (PDF)
- Paricalcitol Injection (Zemplar) (CP.PHAR.270) (PDF)
- Pasireotide (Signifor, Signifor LAR) (CP.PHAR.332) (PDF)
- Patiromer (Veltassa) (CP.PMN.205) (PDF)
- Patisiran (Onpattro) (CP.PHAR.395) (PDF) Effective Date: 8/1/2025
- Pazopanib (Votrient) (CP.PHAR.81) (PDF)
- Peanut Allergen Powder-dnfp (Palforzia) (CP.PMN.220) (PDF)
- Pegaspargase (Oncaspar), Calaspargase Pegol-mknl (Asparlas) (CP.PHAR.353) (PDF)
- Pegcetacoplan (Empaveli, Syfovre) (CP.PHAR.5240 (PDF)
- Pegfilgrastim/Biosimilars, Eflapegrastim, Efbemalenograstim (CP.PHAR.296) (PDF)
- Peginterferon Alfa-2a (Pegasys) (CP.PHAR.89) (PDF)
- Peginterferon Beta-1a (Plegridy) (CP.PHAR.271) (PDF) Effective Date: 8/1/2025
- Pegloticase (Krystexxa) (CP.PHAR.115) (PDF)
- Pegunigalsidase Alfa-iwxj (Elfabrio) (CP.PHAR.512) (PDF)
- Pegvaliase-pqpz (Palynziq) (CP.PHAR.140) (PDF)
- Pegvisomant (Somavert) (CP.PHAR.389) (PDF)
- Pembrolizumab (Keytruda) (CP.PHAR.322) (PDF) Effective Date: 8/1/2025
- Pemetrexed (Alimta, Pemfexy) (CP.PHAR.368) (PDF)
- Pemigatinib (Pemazyre) (CP.PHAR.496) (PDF)
- Penicillamine (Cuprimine) (CP.PCH.09) (PDF)
- Perampanel (Fycompa) (CP.PMN.156) (PDF)
- Perfluorohexyloctane (Miebo) (CP.PMN.290) (PDF)
- Pertuzumab (Perjeta) (CP.PHAR.227) (PDF)
- Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (Phesgo) (CP.PHAR.501) (PDF)
- Pexidartinib (Turalio) (CP.PHAR.436) (PDF)
- Phendimetrazine (CP.PCH.47) (PDF)
- Phentermine (Adipex-P, Lomaira) (CP.PCH.13) (PDF)
- Pilocarpine (Qlosi, Vuity) (CP.PMN.270) (PDF)
- Pimavanserin (Nuplazid) (CP.PMN.140) (PDF)
- Pirfenidone (Esbriet) (CP.PHAR.286) (PDF)
- Pirtobrutinib (Jaypirca) (CP.PHAR.620) (PDF) Effective Date: 8/1/2025
- Pitolisant (Wakix) (CP.PMN.221) (PDF) Effective Date: 8/1/2025
- Plasminogen, Human-tvmh (Ryplazim) (CP.PHAR.513) (PDF)
- Plecanatide (Trulance) (CP.PMN.87) (PDF)
- Plerixafor (Mozobil) (CP.PHAR.323) (PDF)
- Polatuzumab Vedotin-piiq (Polivy) (CP.PHAR.433) (PDF)
- Pomalidomide (Pomalyst) (CP.PHAR.116) (PDF)
- Ponatinib (Iclusig) (CP.PHAR.112) (PDF) Effective Date: 8/1/2025
- Ponesimod (Ponvory) (CP.PHAR.537) (PDF) Effective Date: 8/1/2025
- Potassium Chloride for Oral Solution (Klor-Con Powder) (PDF)
- Pozelimab-bbfg (Veopoz) (CP.PHAR.626) (PDF)
- Pralatrexate (Folotyn) (CP.PHAR.313) (PDF)
- Pramlintide (Symlin) (CP.PMN.129) (PDF)
- Prasterone (Intrarosa) (CP.PMN.99) (PDF)
- Pregabalin (Lyrica, Lyrica CR) (CP.PMN.33) (PDF) Effective Date: 8/1/2025
- Pretomanid (CP.PMN.222) (PDF)
- Progesterone (Crinone, Endometrin) (CP.PMN.243) (PDF)
- Propranolol HCl Oral Solution (Hemangeol) (CP.PCH.51) (PDF)
- Protein C Concentrate, Human (Ceprotin) (CP.PHAR.330) (PDF)
- Prucalopride (Motegrity) (HIM.PA.159) (PDF) Effective Date: 8/1/2025
- Pyrimethamine (Daraprim) (CP.PMN.44) (PDF)
- Quantity Limit Override and Dose Optimization (CP.PMN.59) (PDF)
- Quetiapine Extended-Release (Seroquel XR) (CP.PMN.64) (PDF)
- Quinine Sulfate (Qualaquin) (PDF)
- Quizartinib (Vanflyta) (CP.PHAR.646) (PDF)
- Ramucirumab (Cyramza) (CP.PHAR.119) (PDF)
- Ranibizumab (Byooviz, Cimerli, Lucentis, Susvimo) (CP.PHAR.186) (PDF)
- Rasagiline (Azilect) (HIM.PA.89) (PDF)
- Ravulizumab-cwvz (Ultomiris) (CP.PHAR.415) (PDF)
- Regorafenib (Stivarga) (CP.PHAR.107) (PDF) Effective Date: 8/1/2025
- Relugolix (Orgovyx), Relugolix/Estradiol/Norethinedrone (Myfembree) (CP.PHAR.529) (PDF)
- Remestemcel-L (Ryoncil) (CP.PHAR.474) (PDF)
- Repository Corticotropin Injection (H.P. Acthar Gel, Purified Cortrophin Gel) (HIM.PA.168) (PDF)
- Repotrectinib (Augtyro) (CP.PHAR.667) (PDF)
- Reslizumab (Cinqair) (CP.PHAR.223) (PDF)
- Resmetirom (Rezdiffra) (CP.PHAR.647) (PDF)
- Respiratory syncytial virus vaccine (Abrysvo) (CP.PHAR.658) (PDF)
- Respiratory syncytial virus vaccine (Abrysvo) (CP.PHAR.658) (PDF)
- Retifanlimab-dlwr (Zynyz) (CP.PHAR.629) (PDF) Effective Date: 8/1/2025
- Revumenib (Revuforj) (CP.PHAR.707) (PDF)
- Ribavirin (CP.PHAR.141) (PDF)
- Ribociclib (Kisqali), Ribociclib/Letrozole (Kisqali Femara) (CP.PHAR.334) (PDF)
- Rifabutin (Mycobutin) (CP.PMN.223) (PDF)
- Rifamycin (Aemcolo) (CP.PMN.196) (PDF)
- Rifaximin (Xifaxan) (CP.PMN.47) (PDF)
- Rilonacept (Arcalyst) (CP.PHAR.266) (PDF)
- RimabotulinumtoxinB (Myobloc) (CP.PHAR.233) (PDF)
- Rimegepant (Nurtec ODT) (CP.PHAR.490) (PDF)
- Riociguat (Adempas) (CP.PHAR.195) (PDF)
- Ripretinib (Qinlock) (CP.PHAR.502) (PDF)
- Risdiplam (Evrysdi) (CP.PHAR.477) (PDF) Effective Date: 8/1/2025
- Risedronate (Actonel, Atelvia) (PDF)
- Risperidone Long-Acting Injection (Perseris, Risperdal Consta, Risvan, Rykindo, Uzedy) (CP.PHAR.293) (PDF)
- Rituximab (Rituxan), Rituximab-arrx (Riabni), Rituximab-pvvr (Ruxience), Rituximab-abbs (Truxima), Rituximab-Hyaluronidase (Rituxan Hycela) (CP.PHAR.260) (PDF) Effective Date: 8/1/2025
- Roflumilast (Daliresp, Zoryve) (CP.PMN.46) (PDF)
- Rolapitant (Varubi) (CP.PMN.102) (PDF)
- Romidepsin (Istodax) (CP.PHAR.314) (PDF)
- Romiplostim (Nplate) (CP.PHAR.179) (PDF)
- Romosozumab-aqqg (Evenity) (CP.PHAR.428) (PDF)
- Ropeginterferon Alfa-2b-njft (BESREMi) (CP.PHAR.570) (PDF)
- Rozanolixizumab-noli (Rystiggo) (CP.PHAR.648) (PDF)
- Rucaparib (Rubraca) (CP.PHAR.350) (PDF)
- Rufinamide (Banzel) (CP.PMN.157) (PDF)
- Ruxolitinib (Jakafi, Opzelura) (CP.PHAR.98) (PDF)
- Sacituzumab Govitecan-hziy (Trodelvy) (CP.PHAR.475) (PDF)
- Sacubitril/Valsartan (Entresto) (CP.PMN.67) (PDF)
- Sacubitril/Valsartan (Entresto) (CP.PCH.52) (PDF)
- Safinamide (Xadago) (CP.PMN.113) (PDF)
- Sapropterin Dihydrochloride (Kuvan) (CP.PHAR.43) (PDF)
- Sarecycline (Seysara) (CP.PMN.189) (PDF)
- Sargramostim (Leukine) (CP.PHAR.295) (PDF)
- Satralizumab-mwge (Enspryng) (CP.PHAR.463) (PDF)
- Sebelipase Alfa (Kanuma) (CP.PHAR.159) (PDF)
- Secnidazole (Solosec) (CP.PMN.103) (PDF)
- Seladelpar (Livdelzi) (CP.PHAR.698) (PDF)
- Selexipag (Uptravi) (CP.PHAR.196) (PDF)
- Selinexor (Xpovio) (CP.PHAR.431) (PDF)
- Selpercatinib (Retevmo) (CP.PHAR.478) (PDF) Effective Date: 8/1/2025
- Selumetinib (Koselugo) (CP.PHAR.464) (PDF)
- Semaglutide (Wegovy) (CP.PMN.295) (PDF)
- Setmelanotide (Imcivree) (CP.PHAR.491) (PDF)
- Short Ragweed Pollen Allergen Extract (Ragwitek) (CP.PMN.83) (PDF)
- Sildenafil (Revatio, Liqrev) (CP.PHAR.197) (PDF)
- Sildenafil for ED (Viagra) (CP.PCH.07) (PDF)
- Siltuximab (Sylvant) (CP.PHAR.329) (PDF)
- Siponimod (Mayzent) (CP.PHAR.427) (PDF) Effective Date: 8/1/2025
- Sirolimus Protein-Bound Particles (Fyarro), Topical Gel (CP.PHAR.574) (Hyftor) (PDF)
- Sodium Oxybate (Xyrem, Lumryz) and Calcium, Magnesium, Potassium, and Sodium Oxybate (Xywav) (CP.PMN.42) (PDF) Effective Date: 8/1/2025
- Sodium Phenylbutyrate (Buphenyl, Pheburane, Olpruva) (CP.PHAR.208) (PDF)
- Sodium Phenylbutyrate/Taurursodiol (Relyvrio) (CP.PHAR.584) (PDF)
- Sodium Thiosulfate (Pedmark) (CP.PHAR.610) (PDF)
- Sodium Zirconium Cyclosilicate (Lokelma) (CP.PMN.163) (PDF)
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (HIM.PA.91) (PDF)
- Sofosbuvir (Sovaldi) (HIM.PA.SP2) (PDF)
- Sofosbuvir/Velpatasvir (Epclusa) (HIM.PA.SP1) (PDF)
- Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (HIM.PA.SP63) (PDF)
- Solriamfetol (Sunosi) (CP.PMN.209) (PDF) Effective Date: 8/1/2025
- Sonidegib (Odomzo) (CP.PHAR.272) (PDF)
- Sorafenib (Nexavar) (CP.PHAR.69) (PDF) Effective Date: 8/1/2025
- Sotatercept (Winrevair) (CP.PHAR.657) (PDF)
- Sotorasib (Lumakras) (CP.PHAR.549) (PDF)
- Sparsentan (Filspari) (CP.PHAR.631) (PDF)
- Spesolimab-sbzo (Spevigo) (CP.PHAR.606) (PDF)
- Spinosad (Natroba) (HIM.PA.134) (PDF)
- Step Therapy (HIM.PA.109) (PDF)
- Stiripentol (Diacomit) (CP.PMN.184) (PDF)
- Sunitinib (Sutent) (CP.PHAR.73) (PDF) Effective Date: 8/1/2025
- Sutimlimab-jome (Enjaymo) (CP.PHAR.503) (PDF)
- Suvorexant (Belsomra) (CP.PMN.109) (PDF)
- Suzetrigine (Journavx) (CP.PMN.301) (PDF)
- Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract (Oralair) (CP.PMN.85) (PDF)
- Tadalafil (Adcirca, Alyq, Tadliq) (CP.PHAR.198) (PDF)
- Tadalafil BPH - ED (Cialis, Chewtadzy) (CP.PMN.132) (PDF)
- Tafamidis (Vyndaqel, Vyndamax) (CP.PHAR.432) (PDF) Effective Date: 8/1/2025
- Tafasitamab-cxix (Monjuvi) (CP.PHAR.508) (PDF)
- Talazoparib (Talzenna) (CP.PHAR.409) (PDF)
- Taliglucerase Alfa (Elelyso) (CP.PHAR.157) (PDF)
- Talimogene laherepvec (Imlygic) (CP.PHAR.542) (PDF)
- Talquetamab-tgvs (Talvey) (CP.PHAR.649) (PDF)
- Tapinarof (Vtama) (CP.PMN.283) (PDF)
- Tarlatamab-dlle (Imdelltra) (CP.PHAR.685) (PDF)
- Tasimelteon (Hetlioz, Hetlioz LQ) (CP.PMN.104) (PDF)
- Tavaborole (Kerydin) (CP.PMN.105) (PDF)
- Tazarotene (Arazlo, Fabior, Tazorac) (CP.PMN.244) (PDF)
- Tazemetostat (Tazverik) (CP.PHAR.452) (PDF)
- Tebentafusp-tebn (Kimmtrak) (CP.PHAR.575) (PDF)
- Teclistamab-cqyv (Tecvayli) (CP.PHAR.611) (PDF)
- Tedizolid (Sivextro) (CP.PMN.62) (PDF)
- Teduglutide (Gattex) (CP.PHAR.114) (PDF)
- Telotristat Ethyl (Xermelo) (CP.PHAR.337) (PDF)
- Temozolomide (Temodar) (CP.PHAR.77) (PDF) Effective Date: 8/1/2025
- Temsirolimus (Torisel) (CP.PHAR.324) (PDF)
- Tenapanor (Ibsrela, Xphozah) (CP.PMN.224) (PDF) Effective Date: 8/1/2025
- Tenofovir Alafenamide Fumarate (Vemlidy) (CP.PMN.268) (PDF)
- Teplizumab-mzwv (Tzield) (CP.PHAR.492) (PDF)
- Tepotinib (Tepmetko) (CP.PHAR.530) (PDF) Effective Date: 8/1/2025
- Teprotumumab (Tepezza) (CP.PHAR.465) (PDF)
- Teriflunomide (Aubagio) (CP.PCH.40) (PDF) Effective Date 8/1/2025
- Teriparatide (Forteo, Bonsity) (CP.PHAR.188) (PDF)
- Tesamorelin (Egrifta SV) (CP.PHAR.109) (PDF)
- Testosterone (Androderm) (HIM.PA.87) (PDF)
- Testosterone (Testopel, Jatenzo, Kyzatrex, Tlando) (CP.PHAR.354) (PDF)
- Tetrabenazine (Xenazine) (CP.PHAR.92) (PDF)
- Tezacaftor/Ivacaftor; Ivacaftor (Symdeko) (CP.PHAR.377) (PDF)
- Tezepelumab-ekko (Tezspire) (CP.PHAR.576) (PDF)
- Thalidomide (Thalomid) (CP.PHAR.78) (PDF) Effective Date: 8/1/2025
- Thioguanine (Tabloid) (CP.PHAR.437) (PDF)
- Thyrotropin Alfa (Thyrogen) (CP.PHAR.95) (PDF)
- Timothy Grass Pollen Allergen Extract (Grastek) (CP.PMN.84) (PDF)
- Tiopronin Delayed-Release (Thiola EC) (CP.PHAR.725) (PDF)
- Tisagenlecleucel (Kymriah) (CP.PHAR.361) (PDF)
- Tislelizumab-jsgr (Tevimbra) (CP.PHAR.687) (PDF)
- Tisotumab Vedotin-tftv (Tivdak) (CP.PHAR.561) (PDF)
- Tivozanib (Fotivda) (CP.PHAR.538) (PDF)
- Tobramycin (Bethkis, Kitabis Pak, TOBI, TOBI Podhaler) (CP.PHAR.211) (PDF)
- Tofersen (Qalsody) (CP.PHAR.591) (PDF)
- Tolvaptan (Jynarque, Samsca) (CP.PHAR.27) (PDF)
- Topical Acne Treatment (HIM.PA.71) (PDF)
- Topical Immunomodulators (CP.PMN.107) (PDF)
- Topiramate Extended-Release (Qudexy XR, Trokendi XR) (CP.PMN.281) (PDF)
- Topotecan (Hycamtin) (CP.PHAR.64) (PDF) Effective Date: 8/1/2025
- Toripalimab-tpzi (Loqtorzi) (CP.PHAR.668) (PDF)
- Tovorafenib (Ojemda) (CP.PHAR.686) (PDF)
- Trabectedin (Yondelis) (CP.PHAR.204) (PDF)
- Tralokinumab-ldrm (Adbry) (CP.PHAR.577) (PDF)
- Trametinib (Mekinist) (CP.PHAR.240) (PDF) Effective Date: 8/1/2025
- Trastuzumab/Biosimilars, Trastuzumab-Hyaluronidase (CP.PHAR.228) (PDF) Effective Date: 8/1/2025
- Travoprost Implant (iDose TR) (CP.PHAR.672) (PDF)
- Tremelimumab-actl (Imjudo) (CP.PHAR.612) (PDF)
- Treprostinil (Orenitram, Remodulin, Tyvaso, Tyvaso DPI) (CP.PHAR.199) (PDF)
- Triamcinolone ER Injection (Zilretta) (CP.PHAR.371) (PDF)
- Triclabendazole (Egaten) (CP.PMN.207) (PDF)
- Trientine (Cuvrior, Syprine) (CP.PHAR.438) (PDF)
- Trifarotene (Aklief) (CP.PMN.225) (PDF)
- Trifluridine/Tipiracil (Lonsurf) (CP.PHAR.383) (PDF)
- Triheptanoin (Dojolvi) (CP.PHAR.509) (PDF)
- Triptorelin Pamoate (Trelstar, Triptodur) (CP.PHAR.175) (PDF)
- Tirzepatide (Zepbound) (CP.PMN.298) (PDF) Effective Date: 8/1/2025
- Trofinetide (Daybue) (CP.PHAR.600) (PDF) Effective Date: 8/1/2025
- Tucatinib (Tukysa) (CP.PHAR.497) (PDF)
- Ublituximab-xiiy (Briumvi) (CP.PHAR.621) (PDF)
- Ulcer Therapy Products (CP.PMN.277) (PDF) Effective Date: 8/1/2025
- Uridine Triacetate (Vistogard) (HIM.PA.SP55) (PDF)
- Vadadustat (Vafseo) (CP.PHAR.677) (PDF) Effective Date: 8/1/2025
- Valbenazine (Ingrezza, Ingrezza Sprinkle) (CP.PCH.48) (PDF)
- Valganciclovir (Valcyte) (CP.PCH.06) (PDF)
- Valoctocogene Roxaparvovec-rvox (Roctavian) (CP.PHAR.466) (PDF)
- Valrubicin (Valstar) (CP.PHAR.439) (PDF)
- Vamorolone (Agamree) (CP.PHAR.659) (PDF)
- Vandetanib (Caprelsa) (CP.PHAR.80) (PDF)
- Varenicline (Tyrvaya) (CP.PMN.273) (PDF)
- Velaglucerase Alfa (VPRIV) (CP.PHAR.163) (PDF)
- Velmanase Alfa-tycv (Lamzede) (CP.PHAR.601) (PDF)
- Vemurafenib (Zelboraf) (CP.PHAR.91) (PDF)
- Venetoclax (Venclexta) (CP.PHAR.129) (PDF)
- Verteporfin (Visudyne) (CP.PHAR.187) (PDF)
- Vestronidase Alfa-vjbk (Mepsevii) (CP.PHAR.374) (PDF)
- Vigabatrin (Sabril, Vigafyde) (CP.PHAR.169) (PDF)
- Viloxazine (Qelbree) (CP.PMN.264) (PDF)
- Viltolarsen (Viltepso) (CP.PHAR.484) (PDF)
- Vimseltinib (Romvimza) (CP.PHAR.726) (PDF)
- Vismodegib (Erivedge) (CP.PHAR.273) (PDF)
- Voclosporin (Lupkynis) (CP.PHAR.504) (PDF)
- Vorapaxar (Zontivity) (HIM.PA.146) (PDF)
- Vorasidenib (Voranigo) (CP.PHAR.699) (PDF)
- Voretigene Neparvovec-rzyl (Luxturna) (CP.PHAR.372) (PDF)
- Vorinostat (Zolinza) (CP.PHAR.83) (PDF)
- Vortioxetine (Trintellix) (CP.PMN.65) (PDF)
- Vosoritide (Voxzogo) (CP.PHAR.525) (PDF)
- Voxelotor (Oxbryta) (CP.PHAR.451) (PDF)
- Vutrisiran (Amvuttra) (CP.PHAR.550) (PDF) Effective Date: 8/1/2025
- Zanidatamab-hrii (Ziihera) (CP.PHAR.709) (PDF)
- Zavegepant (Zavzpret) (CP.PHAR.630) (PDF)
- Zenocutuzumab-zbco (Bizengri) (CP.PHAR.713) (PDF) Effective Date: 3/1/2025
- Zilucoplan (Zilbrysq) (CP.PHAR.616) (PDF)
- Ziv-Aflibercept (Zaltrap) (CP.PHAR.325) (PDF)
- Zoledronic Acid (Reclast) (CP.PHAR.59) (PDF)
- Zuranolone (Zurzuvae) (CP.PHAR.650) (PDF)
- zolbetuximab-clzb (Vyloy) (CP.PHAR.705) (PDF)
- lebrikizumab (Ebglyss) (CP.PHAR.704) (PDF)